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Abstract
Studying the pharmacokinetics of antiretroviral drugs in breast milk has important implications for
the health of both the mother and the infant, particularly in resource-poor countries. Breast milk is a
highly complex biological matrix, yet it is necessary to develop and validate methods in this matrix,
which simultaneously measure multiple analytes, as women may be taking any number of drug
combinations to combat human immunodeficiency virus infection. Here, we report a novel extraction
method coupled to high-performance liquid chromatography and tandem mass spectrometry for the
accurate, precise, and specific measurement of 7 antiretroviral drugs currently prescribed to infected
mothers. Using 200 µL of human breast milk, simultaneous quantification of lamivudine (3TC),
stavudine (d4T), zidovudine (ZDV), nevirapine (NVP), nelfinavir (NFV), ritonavir, and lopinavir
was validated over the range of 10–10,000 ng/mL. Intraday accuracy and precision for all analytes
were 99.3% and 5.0 %, respectively. Interday accuracy and precision were 99.4 % and 7.8%,
respectively. Cross-assay validation with UV detection was performed using clinical breast milk
samples, and the results of the 2 assays were in good agreement (P = 0.0001, r = 0.97). Breast milk
to plasma concentration ratios for the different antiretroviral drugs were determined as follows: 3TC
= 2.96, d4T = 1.73, ZDV = 1.17, NVP = 0.82, and NFV = 0.21.
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Women represent 50% of the human immunodeficiency virus (HIV)–infected population
worldwide. Mother-to-child transmission of HIV is the most significant source of HIV
infection in children younger than 10 years.1 In resource-poor settings, more than 40% of all
HIV-1 transmission from mother to infant occurs during breastfeeding.2,3 In these settings,
women must breast-feed their babies due to such issues as inadequate financial resources, lack
of clean water supplies, and stigma. Recent reports also suggest that breastfed babies of HIV-
infected mothers have a significantly lower rate of mortality than formula-fed infants.4
Therefore, a variety of antiretroviral strategies are currently being investigated for prevention
of HIV transmission during breastfeeding.3,5 To support this effort, it is necessary to accurately
characterize the exposure of antiretrovirals in breast milk to understand both the
pharmacodynamics of HIV replication in breast milk and the pharmacology of antiretrovirals
in the breast feeding infant.
Because human milk is a highly complex biological matrix, extracting drugs to accurately
quantify total concentrations is extremely challenging. Milk contains large amounts of proteins
and fats, and the proportions of these vary over time. This complexity necessitates a
sophisticated extraction method for accurate and reproducible results. There are a number of
methods for isolation of drugs from breast milk described in the literature: dialysis,
ultrafiltration, liquid–liquid extraction (LLE), solid phase extraction (SPE), and
immunoaffinity extraction. The most successful of those are based on LLE or SPE principles.
6 However, the validation of these analytical methods is incomplete, primarily due to
difficulties in achieving the requisite precision and accuracy.7
For this investigation, we modified our established multiplex liquid chromatography and
tandem mass spectrometry (LC-MS/MS) method for measuring antiretroviral agents in blood
plasma8 and combined it with a minor modification to our highly efficient extraction technique
for breast milk9 to expand the range of analytes that can be measured in 1 assay. This article
presents the validation of a high-performance liquid chromatography and tandem mass
spectrometry (HPLC-MS/MS) assay for the simultaneous quantification of lamivudine (3TC),
zidovudine (ZDV), stavudine (d4T), nevirapine (NVP), nelfinavir (NFV), lopinavir (LPV),
and ritonavir (RTV) in human breast milk. This method was used to determine the extent of
drug penetration in breast milk compared with blood plasma.
MATERIALS AND METHODS
Materials
3TC, ZDV, d4T, NVP, NFV, RTV, and LPV were obtained from the NIH AIDS Research &
Reference Reagent Program (McKesson HBOC BioServices, Rockville, MD). The internal
standard (IS) cimetidine (CMI) was purchased from Sigma Chemical Company (St Louis,
MO). HPLC grade water and methanol were purchased from Fisher Scientific (Norcross, GA).
Purified compressed nitrogen gas was obtained from National Welder’s Supply (Charlotte,
NC). Breast milk was purchased from Biological Specialty Corporation (Colmar, PA). Three
drug-free pooled human breast milk samples were obtained from multiple healthy nursing
mothers, 1–6 months after delivery.
Instrumentation
A Shimadzu solvent delivery system (Columbia, MD) and a Leap HTC Pal thermostated
autosampler (Carrboro, NC) connected to an Applied Biosystems API 4000 triple quadrupole
mass spectrometer with a TurboSpray ion source (Applied Biosystems, Foster City, CA) were
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used for this analytical study. Tuning, operation, integration, and data analysis were performed
using Analyst software v. 1.4.1 (Applied Biosystems).
Calibration Standards and Quality Control Samples
A stock solution for each anti-HIV drug (analyte) was prepared at a concentration of 1 mg/mL
in a specific ratio of HPLC grade water to methanol. ZDV and NVP required 50% methanol,
NFV and RTV required 60% methanol, and LPV required 70% methanol. The water-soluble
compounds 3TC and d4T were dissolved in 100% HPLC water. The master stock solution was
prepared as a composite of 7 analytes (1 mL each), adjusted in a volumetric flask to the final
concentration of 100 µg/mL in 10 mL using 3 mL of 50% methanol in water. This 100 µg/mL
stock solution was used to prepare 7 intermediate solutions (100, 250, 500, 1000, 5000, 10,000,
and 50,000 ng/mL) in 50% methanol in water. The calibration curve (10, 25, 50, 100, 500,
1000, 5000, and 10,000 ng/mL) was prepared in drug-free pooled breast milk. Quality control
(QC) samples were prepared at 80, 200, 800, 2000, and 8000 ng/mL from a separate 100 µg/
mL master stock solution.
The IS chosen for this method was CMI. CMI 5 mg was weighed and dissolved in HPLC grade
water to achieve a final concentration of 1 mg/mL (IS stock solution). To make the working
IS solution, this stock solution was diluted further in HPLC grade water to a final working
concentration of 2 µg/mL.
Sample Preparation
Whole breast milk was transferred to clean cryovials and stored at −70°C until analysis. Before
extraction, all samples, including blank breast milk samples, clinical samples, calibration
standards, and QC samples, were brought to room temperature.
Disruption of fat globules in breast milk with protein precipitation was modified for an mass
spectrometry (MS) application from a previously published method.9 To each 200 µL sample
of human breast milk (blank, calibrator, QC, or patient sample), 100 µL of normal hexane was
added to assist in disruption of the fat globules. The tubes were capped and vortex mixed for
1.0 minute, sonicated for 1.0 minute, and then mixed with 125 µL of 15% pentafluoropropionic
acid and 700 µL of CMI working IS (2 µg/mL water). All tubes were capped and vortex mixed
for 0.5 minutes and centrifuged at 12,000 rpm (15600g) for 5 minutes at room temperature.
The hexane mixed with the fat formed a solid disk at the top of the solution and allowed the
supernatant to be poured into a conditioned SPE column while leaving the disk behind.9
Solid Phase Extraction
SPE columns (1 mL, 100 mg BOND ELUTE-C18; Varian, Harbor City, CA) were placed in
a vacuum elution manifold (20-SPE system; Waters, Milford, MA). Cartridges were
conditioned with 1 mL of HPLC grade methanol and equilibrated with 1.0 mL of 100 mM
ammonium acetate (pH 7). The clear sample supernatant was carefully transferred to the
conditioned SPE column and allowed to pass through the column bed with minimal suction
(2–5 mm Hg). The column was further washed with 1 mL water. Finally, the analytes were
eluted with 500 µL of 90 % methanol in HPLC water.
The sample eluant was evaporated to dryness under a nitrogen stream at 40°C, and the residue
was reconstituted with 100 µL of a 50:50 mixture of HPLC grade water:HPLC grade methanol
with 0.1% (vol/vol) formic acid. The resulting solution was vortexed for 0.5 minutes and
centrifuged at 18,000g for 3 minutes. The supernatant was transferred to 200 µL HPLC
polypropylene microvials with a support foot (Agilent Technologies), and 10 µL (for negative
mode) or 3 µL (for positive mode) of the supernatant was injected into the HPLC column.
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High-Performance Liquid Chromatography and MS/MS Detection
All samples were analyzed by LC-MS/MS using an Aquasil C18, 50 × 2.1 mm column, with
a 5-µm particle size (Thermo Electron, San Jose, CA), based on a modification of a previously
validated sensitive and specific LC-MS/MS method for measuring antiretroviral agents in
blood plasma.8 Samples were injected twice, first for negative-mode quantification and second
for positive-mode quantification.
Mobile Phase for Negative-Mode Analysis—For negative ion mode using reverse-phase
chromatography, the flow rate was 0.75 mL/min. Initial conditions for mobile phase A (mobile
phase Aneg) were 100% 10 mM ammonium acetate. These conditions were held for 0.7 minute
and the eluant was directed to waste. From 0.7 to 2 minutes, the mobile phase composition
increased linearly to 95% methanol (mobile phase Bneg), and the eluant directed to the mass
spectrometer. The flow was held at 95% mobile phase Bneg until 2.3 minutes. Finally, the
column was equilibrated with 100% mobile phase Aneg. Total runtime, including equilibration,
was 3 minutes per injection.
Mobile Phase for Positive-Mode Analysis—For positive ion mode using reverse-phase
chromatography, the flow rate was 0.5 mL/min. Initial conditions for mobile phase A (mobile
phase Apos) were 100% of 0.1% formic acid in water. This was held for 0.7 minutes and the
eluant was directed to waste. From 0.7 to 3 minutes, the mobile phase composition increased
linearly to 7% of 0.1% formic acid in methanol (mobile phase Bpos), and the eluant directed
to the mass spectrometer. From 3 to 9 minutes, the mobile phase composition increased linearly
to 15% mobile phase Bpos. At 9 minutes, the second period of acquisition started. From 9 to
15 minutes, the mobile phase composition increased linearly to 95% mobile phase Bpos. The
flow was held at 95% Bpos for 30 seconds. After this wash with 95% Bpos, the column was
equilibrated with 100% Apos. Total runtime, including equilibration, was 18 minutes per
injection.
Linearity
Linearity was assessed using 3 calibration curves run on separate days. For validation, each
point on the calibration curve was run in duplicate (2 separate extractions). After validation,
single calibration curves were used for routine clinical sample testing. Standard curve equations
for each analyte were derived using weighted (1/x2) linear least-squares regression analysis.
Limits of Detection and Quantification Accuracy and Precision
The lower limit of quantification was defined as the concentration for which both the relative
standard deviation (RSD, also called the coefficient of variation) and the percent deviation
from the nominal concentration were less than 20%. Additionally, the lower limit of
quantification had to have a signal to noise ratio above 5. The upper limit of quantitation was
defined as the concentration for which both the RSD and the percent deviation from the nominal
concentration were less than 15%.10 The lower limit of detection was defined as a signal to
noise ratio of 3:1.
Accuracy and precision were quantified using 5 concentrations of QC samples covering the
expected clinical concentrations: 80, 200, 800, 2000 and 8000 ng/mL. The calculated
concentrations were compared with these nominal concentrations.
Specificity, Selectivity, Recovery, Matrix Effect, and Stability
Six blank human breast milk samples were prepared to determine the specificity, selectivity,
recovery, and matrix effect of the analytical method. One half of the samples (“blank breast
milk,” n = 3) were spiked with IS only, and one half of the samples (“double blank breast milk,”
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n = 3) were not spiked with anything. The double blank breast milk samples received 700 µL
of IS-free HPLC grade water to maintain sample composition. With the exception of the
addition of IS, all 6 samples were prepared and analyzed as described above. The results of the
double blank breast milk samples were investigated for peaks that might interfere either with
the detection of the 7 drugs of interest or with the IS. Peaks with an area >200 units and a signal
to noise ratio > 1:3 at the retention time of any of the 7 analytes or of the IS were considered
to be interfering.
To determine analyte recovery, peak areas of spiked breast milk (test) replicates were compared
with those of spiked neat reconstitution solution (control) replicates of equal nominal
concentration. Test and control replicates at 200 ng/mL (n = 6 each) and 2000 ng/mL (n = 6
each) were prepared. Test samples were extracted and analyzed as described above.
Possible matrix effects were investigated according to the method of Taylor.11 First, 18 double
blank breast milk (test) samples were extracted as described above. At the reconstitution step,
solutions containing 80 ng/mL, 200 ng/mL (n = 5), 2000 ng/mL (n = 5), or 8000 ng/mL (n =
5) of all 7 drugs of interest were used. After analysis, peak areas of these reconstituted test
samples were compared with those of unextracted neat control samples at equal concentrations.
Possible matrix effects were calculated as percent deviation from values observed with standard
solutions.
Samples were tested for stability in breast milk at room temperature for 24 hours, in breast
milk at 4°C for 72 hours, and in the reconstitution solution at room temperature in the HPLC
autosampler for 24 hours.
Analysis of Clinical Samples and Cross-Validation
The clinical samples were obtained from the Breastfeeding, Antiretroviral, and Nutrition study.
3,12 The study was approved by the Institutional Review Boards at the University of North
Carolina at Chapel Hill and the National Health Science Research Committee in Malawi, and
all subjects gave informed consent before enrolling. This study was designed to evaluate
antiretroviral and nutrition interventions to reduce MTCT of HIV during breastfeeding.
Clinical samples were obtained from women who had been randomized to receive antiretroviral
therapy while breastfeeding. These samples were analyzed on 2 different days using 2 different
standard curves. Data in both runs were compared to evaluate reproducibility of the
methodology, performed as a requisite part of the validation process to ensure optimal interday
LC-MS/MS detection. To confirm the quality of the data obtained by HPLC-MS/MS, these
results were also compared (using Spearman rho) with those obtained from a validated LC–
diode array detection assay.9
RESULTS
LC-MS/MS Analysis
Negative-Mode Analysis—To improve signal intensity of negatively charged drugs, a
separate injection using a mobile phase more amenable to producing negative ions was used.
d4T (222.9→42.0), ZDV (266.0→223.0), and CMIneg (IS, 250.3→156.9) were monitored
using multiple reaction monitoring (MRM) in negative ion mode using reverse-phase
chromatography at 0.75 mL/min. As source fragmentation of ZDV produced apparent d4T,
care was taken to ensure chromatographic separation between ZDV and d4T. An injection of
10 µL of reconstituted sample was required for an adequate d4T signal. Chromatograms for
the negative analysis mode for the low QC are shown in Figure 1.
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Positive-Mode Analysis—To improve signal intensity of positively charged drugs, a
separate injection using a mobile phase more amenable to producing positive ions was used.
In addition, a 2-period acquisition was used to reduce duty cycle as a means of further increasing
signal intensity. The first period monitored the transitions (MRM) for 3TC (230.1→112.1),
ZDV (268.3→127.1), and CMIpos (IS, 253.1→159.3). The second period monitored the
transitions for NVP (267.2→226.1), NFV (568.3→467.2), LPV (629.4→447.3), and RTV
(721.0→268.0). An injection of 3 µL was required. Chromatograms for the 2-period analysis
are shown in Figure 2 using the low QC. All transitions for the 7 analytes are summarized in
Table 1.
Assay Validation Linearity and Limits of Quantification
Standard curves over 3 days for d4T and ZDV were quantified using the peak area ratios
(analyte peak area to ISneg peak area) of the spiked calibration standards (10–10,000 ng/mL).
Standard curves over 3 days for 3TC, ZDV, NVP, NFV, RTV, and LPV were quantified using
the peak area ratios (analyte peak area to ISpos peak area) of the spiked calibration standards
(10–10,000 ng/mL). A weighted (1/x2) least-squares regression analyses were used for all
analytes.
All drugs were linear over 10–10,000 ng/mL. Standard curve data are summarized in Table 2.
The accuracy was between 80% and 120% for all levels (n = 3) and LLOQ (n = 5). At the
LLOQ, accuracy and co-efficient of variation (CV%) were 117%–88% and 1.3%–8.4%,
respectively, for all analytes. Calibration standard curves yielded correlation coefficients
consistently ≥0.990 for all analytes across 3 different days. Concentrations ranging from 10 to
10,000 ng/mL were sufficient to quantify 3 nucleoside analogue reverse transcriptase inhibitors
(3TC, d4T, and ZDV), 1 nonnucleoside reverse transcriptase inhibitor (NVP), and 3 protease
inhibitors (NFV, RTV, and LPV).
Assay Accuracy and Precision
Accuracy and precision of the analytical procedure were evaluated using 3 concentrations of
QC samples assayed in 3 replicates on 3 different days. The concentrations of the QC samples
were back-calculated from daily calibration curves. Intra- and interday accuracy and precision
for these concentrations are presented in Table 3. Accuracy for all analytes was within the
acceptance limits (±15% of the nominal) specified by Shah et al.10 The ≤15% RSD criteria for
repeatability (within-day precision) and time-different intermediate precision (between-day
precision) were fulfilled for all analytes. Using the mean values, overall intraday accuracy and
precision for all analytes were 99.3% and 5.0%, respectively, and interday accuracy and
precision were 99.4% and 7.8%, respectively.
Selectivity, Recovery, Matrix Effect, and Stability
No peaks interfering with any of the 7 analytes or the IS were detected. Figure 2 illustrates the
peaks in both positive and negative modes for the low QC sample.
Extraction recovery and matrix effects for all analytes are listed in Table 2. The extraction
method demonstrated high extraction efficiency for all compounds and IS. Overall, recoveries
of 92.6% (range 86.7%–99.3%) with an RSD of 5% (range 3.5%–6.4%) were obtained.
All analytes were stable under all conditions tested. Drugs retained greater than 92% of their
original concentration in milk for 24 hours at room temperature, greater than 97% of their
concentration for 72 hours at 4°C, and greater than 95% of their concentration in the
reconstitution solution for 24 hours at room temperature in the HPLC autosampler.
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Reproducibility of Clinical Samples and Cross-Assay Validation
LC-MS/MS results for 15 clinical breast milk samples were compared in 2 different runs on 2
separate days. The average concentrations are represented and the percent deviation between
the 2 runs for each analyte is shown in Figure 3.
Finally, the results obtained by LC-MS/MS were compared with those obtained by the LC–
diode array detection. Figure 4 plots the concentrations obtained by both methods with
reference to the line of unity (m = 1) and illustrates good agreement between the assays’ final
results. Spearman rho on these values was 0.97, with a P value of < 0.0001.
Breast Milk to Plasma Ratio
The breast milk concentrations were compared with plasma concentrations obtained
concurrently in these women and measured using a validated UV method.13 The breast milk
to blood plasma drug concentration ratios are listed in Table 4. The mean breast milk to blood
plasma concentration ratios were >1 for 3TC, d4T, and ZDV (2.96, 1.73, and 1.17, respectively)
and <1 for NVP and NFV (0.82 and 0.21, respectively). Of 60 samples analyzed for mothers
taking LPV and RTV, no drug was detected in breast milk.
DISCUSSION
Human milk is an optimal form of nourishment for infants.14 It is a complex biological matrix,
whose components vary with the time of day, the day of lactation, from mother to mother, and
among species.15 However, breast milk is also the source for HIV infection among a significant
proportion of children in the developing world. Antiretroviral therapy, given to the mother
during the baby’s first months of life, is being investigated as a possible intervention to prevent
HIV transmission. As such, there is a need for accurately measuring antiretroviral drugs in
breast milk to best understand the viral dynamics of HIV in this matrix and to accurately predict
drug exposure in the infant.
In testing whether our UV method for blood plasma protease inhibitor quantitation16 could be
used for breast milk, we had difficulties quantifying RTV and LPV and were only able to
measure NVP and NFV accurately after LLE. Even after using a previously reported SPE
technique9 (with modifications as described above), we found significant matrix interference
that eliminated the possibility of accurate measures using LC-UV detection. Therefore, it was
necessary to proceed to a highly selective detection method such as MS/MS.
MS/MS is the most advanced technology for small molecule analysis today.17 However, for
any biological matrix, it is not useful without a good sample extraction method and an efficient
chromatographic separation. MS/MS detection has several technical problems, which can limit
its use in clinical pharmacology applications. These include ion suppression and ion
enhancement due to matrix effects, limited dynamic range, and carryover. In this study, we
overcame the dynamic range problem by modifying a previous method8 and widened the range
from 1–500 to 10–10,000 ng/mL.
Additionally, extensive sample cleanup was needed before analysis. In this study, we modified
a highly efficient extraction technique9 to include 3 additional protease inhibitors. This method
now allows simultaneous extraction and analysis of nonpolar and highly lipophilic compounds
(RTV and LPV) with relatively polar compounds (3TC and d4T)
To accommodate the lipophilicity of protease inhibitors, an increased amount of
pentafluoropropionic acid (to 125 µL) was used to completely disrupt the fat globules.
Additionally, increasing the organic portion of the eluting solution from 70% methanol (which
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was sufficient for eluting only 3TC, d4T, ZDV, and NVP) to 90% was necessary to elute RTV
and LPV and increase extraction efficiency.
Electrospray ionization in both the positive and negative ion mode was used to detect all
analytes. Therefore, it was critical for an IS to be chosen, which could be ionized in both
negative and positive modes. Although an isotopically labeled IS may negate matrix effects,
these can be very expensive to purchase or produce. Our CMI IS fulfilled the requirements of
an IS and was less expensive. CMI, also used in our previous method,8 could be ionized in
both modes. The extraction efficiency and matrix effect for CMI are shown in Table 2. Figure
5 illustrates a negative ion mode chromatogram for d4T and CMI in a clinical sample, and d4T
concentration calculated as 213.8 ng/mL.
CONCLUSIONS
This HPLC-MS/MS assay is comprehensive and capable of analyzing the most commonly
investigated antiretroviral drugs for preventing vertical HIV transmission during breastfeeding.
A modification of our highly efficient extraction technique for measuring antiretroviral drug
concentrations in breast milk9 was made to include 3 protease inhibitors (NFV, RTV and LPV)
in the analysis. Additionally, modifications to a previously published LC-MS/MS method8
included (1) improving the peak intensity for d4T by using negative mode, in an independent
injection; (2) optimizing injection volumes for positive mode (3 µL) to avoid detector saturation
and negative mode (10 µL) to increase sensitivity; (3) monitoring the 13 C detector transitions
to avoid detector saturation; and (4) improving analyte sensitivity in positive mode by using 2
periods. Finally, based on our experience with this extraction method, the following sample
treatment procedures should be followed for optimal results: (1) breast milk should be
homogenized at room temperature before spiking with anti-retroviral drugs; (2) a bulk amount
of breast milk calibrators, QCs, and blanks should be prepared at one time through intermediate
stock solutions, not through serial dilution; (3) mix the drugs well using gentle agitation; and
(4) continually mix the samples while aliquoting to ensure equal distribution of fat (and drug)
in each tube at all concentration levels (this is particularly important for highly fat-soluble
compounds).
This approach is recommended for simultaneously analyzing polar and nonpolar compounds
in human breast milk in addition to other matrices containing large amounts of fat.
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Chromatogram of low QC (80 ng/mL) in negative mode. The figure illustrates peaks for ZDV
(266.0/223.0), d4T (22.9/42.0), and CMI (250.3/156.9) ion pair.
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A, Chromatogram of low QC (80 ng/mL) in positive-mode first period. The figure illustrates
peaks for ZDV (268.3/127.1), CMI (253.1/159.3), and 3TC (230.13/112.2) ion pair. B,
Chromatogram of low QC (80 ng/mL) in positive-mode second period. The figure illustrates
peaks for RTV (721.0/268.0), LPV (629.4/447.3), NFV (568.3/467.2), and NVP (267.1/226.1)
ion pair.
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Percent deviation between 2 LC-MS/MS runs for 15 clinical samples.
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Comparison of results between LC-MS/MS and LC-diode array detection (UV).
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Chromatogram in negative mode for 1 clinical sample. The figure illustrates peaks for d4T
(222.9/42.0) and IS CMI (250.3/156.9) ion pairs.
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TABLE 1











3TC 222.9 Positive 230.1 112.2
D4T 224.1 Negative 222.9 42.0
CMI 252.3 Negative 250.9 156.9
CMI 252.3 Positive 253.1 159.3
ZDV 267.1 Negative 265.7 222.9
ZDV 267.1 Positive 268.3 127.1
NVP 266.3 Positive 267.2 226.1
NFV 567.0 Positive 568.3 467.2
RTV 721.0 Positive 721.4 268.1
LPV 627.8 Positive 628.7 447.3
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TABLE 2







3TC 10–10,000 0.994 95.4 −1.9
D4T 10–10,000 0.995 88.5 −6.0
ZDV 10–10,000 0.998 92.6 1.3
NVP 10–10,000 0.994 99.3 2.0
NFV 10–10,000 0.992 89.0 −3.6
RTV 10–10,000 0.996 86.7 6.4
LPV 10–10,000 0.993 96.6 4.5
CMI Negative 82.0 −1.8
CMI Positive 82.0 3.3
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TABLE 3
Summary of Accuracy and Precision for Method Validation of 7 Antiretroviral Drugs













3TC 80 110 6.9 99 7.9
200 96 4.6 97 5.1
800 101 2.4 103 5.2
2000 101 6.4 104 2.8
8000 110 9.1 111 12.2
D4T 80 112 3.9 108 12.9
200 89 7.4 95 13.0
800 84 4.5 87 4.6
2000 86 3.2 98 10.7
8000 103 11.5 96 12.2
ZDV 80 105 6.9 113 7.3
200 91 5.9 92 4.3
800 96 2.4 95 7.7
2000 95 6.3 100 2.1
8000 113 3.0 107 9.0
NVP 80 116 3.6 110 7.3
200 101 4.4 99 5.3
800 103 4.9 104 7.9
2000 107 3.5 106 3.6
8000 106 4.0 107 7.3
NFV 80 109 6.7 108 12.1
200 105 0.5 99 9.4
800 100 3.1 98 7.3
2000 104 3.3 91 9.9
8000 98 3.2 94 10.2
RTV 80 107 5.8 116 9.8
200 104 2.8 104 7.9
800 96 6.6 103 9.9
2000 99 5.7 107 7.0
8000 104 1.9 99 9.4
LPV 80 114 5.5 116 10.8
200 103 0.9 102 5.6
800 104 6.4 108 11.9
2000 92 12.2 89 9.5
8000 90 10.5 88 8.2
CV, co-efficient of variation.
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TABLE 4






















2.96 1.73 1.17 0.82 0.21 NA NA
NA, not available; BM, breast milk; BP, blood plasma.
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